Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas

ConclusionMRS effectively differentiates TDLs from high-grade gliomas. Therefore, the clinical use of MRS is likely to enhance patient outcomes.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research